Primary chronic cold agglutinin disease: An update on pathogenesis, clinical features and therapy

References

• Dacie J. The auto-immune haemolytic anaemias: Introduc-rion. In: Dacie J, editor. The haemolytic anaemias., vol. 3 London: Churchill Livingstone; 1992. p 1–5.
   Google Scholar
• Petz LD, Garratty G. Classification and clinical characteristics of autoimmune hemolytic anemias. In: Petz LD, Garratty G, editors. Immune hemolytic anemias. Philadelphia, PA: Churchill Livingstone; 2004. p 61–131.
   Google Scholar
• Berentsen S, Ulvestad E, Langholm R, Beiske K, Hjorth-Hansen H, Ghanima W, Sorbo JH, Tjonnffprd GE. Primary chronic cold agglutinin disease: A population based clinical study of 86 patients. Haematologica 2006;91(4):460–466.
   PubMed Web of Science ®Google Scholar
• Ulvestad E, Berentsen S, Bo K, Shammas FV. Clinical immunology of chronic cold agglutinin disease. Eur J Haematol 1999;63(4):259–266.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Cold hemolytic syndrome. Hematology Am Soc Hematol Educ Program 2006;19–23.
   PubMedGoogle Scholar
• Landsteiner K. Über Beziehungen zwischen dem Blutserum und den Körperzellen. Münchener medizinische Wochens-chrift 1903;50:1812–1814.
   Google Scholar
• Clough MC, Richter IM. A study of an auto-agglutinin occurring in human serum. Johns Hopkins Hosp Bull 1918;29:86–93.
   Google Scholar
• Rosenthal F, Corten M. Über das Phänomen der Auto-hämagglutination und iiber die Eigenscaften der Kältehämag-glutinine. Folia Haematol (Leipzig) 1937;58:64–90.
   Google Scholar
• Dacie J. Auto-immune haemolytic anaemia (AIHA): Cold antibody syndromes I: Idiopathic types: Clinical presentation and haematological and serological findings. In: Dacie J, editor. The haemolytic anaemias., vol. 3 London: Churchill Livingstone; 1992. p 210–239.
   Google Scholar
• Schubothe H. The cold hemagglutinin disease. Semin Hematol 1966;3(1):27–47.
   PubMedGoogle Scholar
• Olesen H. Thermodynamics of the cold agglutinin reaction. Scand J Chin Lab Invest 1966;18(1):1–15.
   PubMed Web of Science ®Google Scholar
• Rosse WF, Adams JP. The variability of hemolysis in the cold agglutinin syndrome. Blood 1980;56(3):409–416.
   PubMed Web of Science ®Google Scholar
• Zilow G, Kirschfink M, Roelcke D. Red cell destruction in cold agglutinin disease. Infusionsther Transfusionsmed 1994;21(6):410–415.
   PubMedGoogle Scholar
• Rorvik K. The syndrome of high-titre cold haemagglutination; a survey and a case report. Acta Med Scand 1954;148(4): 299–308.
   PubMedGoogle Scholar
• Jaffe CJ, Atkinson JP, Frank MM. The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man. J Chin Invest 1976;58(4):942–949.
   Google Scholar
• Kirschfink M, Knoblauch K, Roelcke D. Activation of complement by cold agglutinins. Infusionsther Transfu-sionsmed 1994;21(6):405–409.
   Google Scholar
• Nydegger UE, Kazatchkine MD, Miescher PA. Immuno-pathologic and clinical features of hemolytic anemia due to cold agglutinins. Semin Hematol 1991;28(1):66–77.
   Google Scholar
• Gertz MA. Cold agglutinin disease. Haematologica 2006; 91(4):439–441.
   PubMed Web of Science ®Google Scholar
• Dacie J. Treatment and prognosis of cold-antibody AIHA. In: Dacie J, editor. The haemolytic anaemias., vol. 3 London: Churchill Livingstone; 1992. p 502–508.
   Google Scholar
• Petz LD, Garratty G. Management of autoimmune hemolytic anemias. In: Petz LD, Garratty G, editors. Immune hemolytic anemias. Philadelphia, PA: Churchill Livingstone; 2004. p 401–458.
   Google Scholar
• Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis: An 18-year study of 865 cases referred to a regional transfusion centre. Br Med J (Chin Res Ed) 1981;282(6281):2023–2027.
   PubMed Web of Science ®Google Scholar
• Genty I, Michel M, Hermine O, Schaeffer A, Godeau B, Rochant H. Characteristics of autoimmune hemolytic anemia in adults: Retrospective analysis of 83 cases. Rev Med Interne 2002;23(11):901–909.
   PubMed Web of Science ®Google Scholar
• Lyckholm U, Edmond MB. Seasonal hemolysis due to cold-agglutinin syndrome. N Engl J Med 1996;334(7):437.
   PubMed Web of Science ®Google Scholar
• Ulvestad E. Paradoxical haemolysis in a patient with cold agglutinin disease. Eur J Haematol 1998;60(2):93–100.
   PubMed Web of Science ®Google Scholar
• Ulvestad E, Berentsen S, Mollnes TE. Acute phase haemolysis in chronic cold agglutinin disease. Scand J Immunol 2001;54(1-2):239–242.
   Google Scholar
• Wiener AS, Unger LJ, Cohen L, Feldman J. Type-specific cold auto-antibodies as a cause of acquired hemolytic anemia and hemolytic transfusion reactions: Biologic test with bovine red cells. Ann Intern Med 1956;44(2):221–240.
   PubMed Web of Science ®Google Scholar
• Dacie J. Auto-immune haemolytic anaemia (AIHA): Cold-antibody syndromes II: Immunochemistry and specificity of the antibodies; serum complement in auto-immune haemoly-tic anaemia. In: Dacie J, editor. The haemolytic anaemias., vol. 3 London: Churchill Livingstone; 1992. p 240–295.
   Google Scholar
• Dellagi K, Brouet JC, Schenmetzler C, Praloran V. Chronic hemolytic anemia due to a monoclonal IgG cold agglutinin with anti-Pr specificity. Blood 1981;57 (1) :189–191 .
   PubMed Web of Science ®Google Scholar
• Monteverde A, Rivano MT, Allegra GC, Monteverde Al, Zigrossi P, Baglioni P, Gobbi M, Falini B, Bordin G, Pileri S. Essential mixed cryoglobulinemia, type II: A manifestation of a low-grade malignant lymphoma? Clinical-morphological study of 12 cases with special reference to immunohistochem-ical findings in liver frozen sections. Acta Haematol 1988;79(1):20–25.
   PubMed Web of Science ®Google Scholar
• Kuenn JW, Weber R, Teague PO, Keitt AS. Cryopathic gangrene with an IgM lambda cryoprecipitating cold agglutinin. Cancer 1978;42(4): 1826–1833.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Bo K, Shammas FV, Myking AO, Ulvestad E. Chronic cold agglutinin disease of the "idiopathic" type is a premalignant or low-grade malignant lymphoproliferative disease. APMIS 1997;105(5):354–362.
   PubMed Web of Science ®Google Scholar
• Lewis SM, Szur L, Dacie JV. The pattern of erythrocyte destruction in haemolytic anaemia, as studied with radioactive chromium. Br J Haematol 1960;6:122–139.
   Google Scholar
• Rosse WF, Adams J, Logue G. Hemolysis by complement and cold-reacting antibodies: Time and temperature requirements. Am J Hematol 1977;2(3):259–270.
   Google Scholar
• Rosse WF, Hillmen P, Schreiber AD. Immune-mediated hemolytic anemia. Hematology Am Soc Hematol Educ Program 2004;48–62.
   Google Scholar
• Christenson WN, Dacie JV, Croucher BE, Charlwood PA. Electrophoretic studies on sera containing high-titre cold haemagglutinins: Identification of the antibody as the cause of an abnormal gamma 1 peak. Br J Haematol 1957;3(3): 262–275.
   PubMed Web of Science ®Google Scholar
• Fudenberg HH, Kunkel HH. Physical properties of the red cell agglutinins in acquired hemolytic anemia. J Exp Med 1957;106(5):689–702.
   PubMed Web of Science ®Google Scholar
• Harboe M, Deverill J. Immunochemical properties of cold haemagglutinins. Scand J Haematol 1964;61:223–237.
   Google Scholar
• Harboe M, van Furth R, Schubothe H, Lind K, Evans RS. Exclusive occurrence of K chains in isolated cold haemagglu-tinins. Scand J Haematol 1965;2(3):259–266.
   PubMedGoogle Scholar
• Harboe M, Torsvik H. Protein abnormalities in the cold haemagglutinin syndrome. Scand J Haematol 1969;6(6): 416–426.
   PubMedGoogle Scholar
• Stone MJ, McElroy YG, Pestronk A, Reynolds JL, Newman JT, Tong AW. Human monoclonal macroglobulins with antibody activity. Semin Oncol 2003;30(2):318–324.
   PubMed Web of Science ®Google Scholar
• Hughey CT, Brewer JW, Colosia AD, Rosse WE, Corley RB. Production of IgM hexarners by normal and autoimmune B cells: Implications for the physiologic role of hexameric IgM. J Immunol 1998;161 (8): 4091–4097 .
   Google Scholar
• Randall TD, King LB, Corley RB. The biological effects of IgM hexamer formation. Eur J Immunol 1990;20(9): 1971–1979.
   PubMedGoogle Scholar
• Pascual V, Victor K, Spellerberg M, Hamblin TJ, Stevenson FK, Capra JD. VH restriction among human cold agglutinins. The VH4-21 gene segment is required to encode anti-I and anti-i specificities. J Immunol 1992; 149(7):2337–2344.
   PubMed Web of Science ®Google Scholar
• Thorpe SJ, Boult CE, Stevenson FK, Scott ML, Sutherland J, Spellerberg MB, Natvig JB, Thompson KM. Cold agglutinin activity is common among human monoclonal IgM Rh system antibodies using the V4-34 heavy chain variable gene segment. Transfusion 1997;37(11-12):1111–1116.
   PubMed Web of Science ®Google Scholar
• Potter KN. Molecular characterization of cold agglutinins. Transfus Sci 2000;22(1-2):113–119.
   PubMedGoogle Scholar
• Jefferies LC, Carchidi CM, Silberstein LE. Naturally occurring anti-i/I cold agglutinins may be encoded by different VH3 genes as well as the VH4.21 gene segment. J Chin Invest 1993;92 (6) :2821–2833.
   PubMed Web of Science ®Google Scholar
• Jonsen J, Kass E, Harboe M. Complement and complement components in acquired hemolytic anemia with high titer cold antibodies. Acta Med Scand 1961;170:725–729.
   Google Scholar
• Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H, Ghanima W, Shammas FV, Tjonnfjord GE. Rituximab for primary chronic cold agglutinin disease: A prospective study of 37 courses of therapy in 27 patients. Blood 2004;103(8):2925–2928.
   PubMed Web of Science ®Google Scholar
• Golay J, Cittera E, Di Gaetano N, Manganini M, Mosca M, Nebuloni M, van Rooijen N, Vago L, Introna M. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 2006;91 (2) : 176–183 .
   Google Scholar
• Harjunpaa A, Junnikkala S, Men i S. Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000;51(6):634–641.
   PubMed Web of Science ®Google Scholar
• Silberstein LE, Robertson GA, Harris AC, Moreau L, Besa E, Nowell PC. Etiologic aspects of cold agglutinin disease: Evidence for cytogenetically defined clones of lymphoid cells and the demonstration that an anti-Pr cold autoantibody is derived from a chromosomally aberrant B cell clone. Blood 1986;67(6): 1705–1709.
   PubMed Web of Science ®Google Scholar
• Berentsen S. Chronic cold agglutinin disease. Tidsskr Nor Laegeforen 1995;115 (4): 473–475 .
   PubMedGoogle Scholar
• Isaksson E, Bjorkholm M, Holm G, Johansson B, Nilsson B, Mellstedt H, Osterborg A. Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): Association with malignant transform-ation. Br J Haematol 1996;92(1):71–76.
   Google Scholar
• Berger F, Isaacson PG, Pins MA, Harris NU, Müller-Hermelink HK, Nathwani BN, Swerdlow SH. Lymphoplasmacytic lymphoma/Waldenström macro-globulinemia. In: Jaffe ES, Harris NU, Stein H, Vardiman J, editors. Pathology and genetics of tumours of the haemato-poietic and lymphoid tissues. WHO classification of tumours., vol. 3 Lyon: IARC Press; 2001. p 132–134.
   Google Scholar
• Owen RG, Treon SP, Al Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, San Miguel JF, Branagan AR, Dimopoulos MA. Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30(2):110–115.
   Google Scholar
• Michaux L, Dierlamm J, Wlodarska L, Criel A, Louwagie A, Ferrant A, Hagemeijer A, Van den BH. Trisomy 3q11-q29 is recurrently observed in B-cell non-Hodgkin's lymphomas associated with cold agglutinin syndrome. Ann Hematol 1998;76(5):201–204.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Chen J, Lim S, Chong SM, Kueh YK, Lee SH. Translocation (8;22) in cold agglutinin disease associatedwith B-cell lymphoma. Cancer Genet Cytogenet 2004;152(1): 66–69.
   PubMed Web of Science ®Google Scholar
• Crisp D, Pruzanski W. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am J Med 1982; 72(6):915–922.
   PubMed Web of Science ®Google Scholar
• Dacie J. Haemolytic anaemias associated with malignant lymphomas other than Hodgkin's disease and chronic lymphocytic leukaemia (CLL). In: Dacie J, editor. The haemolytic anaemias., vol. 4 London: Churchill Livingstone; 1995. p 27–40.
   Google Scholar
• Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol 2002;69(4):258–271.
   PubMed Web of Science ®Google Scholar
• O'Connor BM, Clifford JS, Lawrence WD, Logue GL. Alpha-interferon for severe cold agglutinin disease. Ann Intern Med 1989;111 (3):255–256.
   PubMed Web of Science ®Google Scholar
• Hillen HF, Bakker SJ. Failure of interferon-alpha-2b therapy in chronic cold agglutinin disease. Eur J Haematol 1994; 53(4):242–243.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Tjonnfiord GE, Shammas FV, Bergheim J, Hammerstrom J, Langholm R, Ulvestad E. No response to cladribine in five patients with chronic cold agglutinin disease. Eur J Haematol 2000;65(1):88–90.
   Google Scholar
• Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Chin Oncol 1997; 15(10): 3266–3274.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Chin Oncol 1998;16(8):2825–2833.
   PubMed Web of Science ®Google Scholar
• Reff ME, Garner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83(2):435–445.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Tjonnfiord GE, Brudevold R, Gjertsen BT, Langholm R, Lokkevik E, Sorbo JH, Ulvestad E. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol 2001;115(1):79–83.
   PubMed Web of Science ®Google Scholar
• Schollkopf C, Kjeldsen L, Bjerrum OW, Mounts-Andersen HT, Nielsen JL, Christensen BE, Jensen BA, Pedersen BB, Taaning EB, Klausen TW, Birgens H. Rituximab in chronic cold agglutinin disease: A prospective study of 20 patients. Leuk Lymphoma 2006;47(2):253–260.
   PubMed Web of Science ®Google Scholar
• Lee EJ, Kueck B. Rituxan in the treatment of cold agglutinin disease. Blood 1998;92 (9):3490–3491.
   PubMed Web of Science ®Google Scholar
• Finazzi G. Rituximab in autoimmune cytopenias: For which patients? Haematologica 2002;87 (2):113–114.
   PubMed Web of Science ®Google Scholar
• Camou F, Viallard JF, Pellegrin JL. Rituximab in cold agglutinin disease. Rev Med Interne 2003;24(8):501–504.
   PubMedGoogle Scholar
• Cesana C, Barbarano L, Miqueleiz S, Lucchesini C, Ricci F, Varettoni M, Filippini D, Lazzarino M, Morra E. Clinical characteristics and outcome of immunoglobulin M related disorders. Chin Lymphoma 2005;5(4):261–264.
   Google Scholar
• Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006;108(8):2520–2530.
   PubMed Web of Science ®Google Scholar
• Kriangkum J, Taylor BJ, Treon SP, Mant MJ, Belch AR, Pilarski LM. Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood 2004;104(7):2134–2142.
   PubMed Web of Science ®Google Scholar
• Ulvestad E, Aarseth JH, Vedeler C, Nyland H, Myhr KM. The effects of interferon-alpha2a on concentrations of immuno-globulins, complement and lymphocytes in patients with multiple sclerosis. Scand J Immunol 2004;59 (1):103–108.
   PubMed Web of Science ®Google Scholar
• Sivaraman S, Venugopal P, Ranganathan R, Deshpande CG, Huang X, Jajeh A, Gregory SA, O'Brien T, Preisler HD. Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia. Cytokines Cell Mol Ther 2000;6(2):81–87.
   PubMed Web of Science ®Google Scholar
• Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59. Blood 2001;98(12):3383–3389.
   PubMed Web of Science ®Google Scholar
• Binstadt BA, Geha RS, Bonilla FA. IgG Fc receptor polymorphisms in human disease: Implications for intrave-nous immunoglobulin therapy. J Allergy Clin Immunol 2003;111 (4): 697–703 .
   Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99(3):754–758.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macro-globulinemia. J Chin Oncol 2005;23(3):474–481.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Kantarjian H, Keating MJ. Purine analogs in chronic lymphocytic leukemia and Waldenstrom's macroglo-bulinemia. Ann Oncol 1996;7 (Suppl. 6):S27–S33.
   PubMedGoogle Scholar
• Leblond V, Choquet S. Fludarabine in Waldenstrom's macroglobulinemia. Semin Oncol 2003;30(2):239–242.
   PubMed Web of Science ®Google Scholar
• Jacobs A. Cold agglutinin hemolysis responding to fludarabine therapy. Am J Hematol 1996;53(4):279–280.
   PubMed Web of Science ®Google Scholar
• Di Gaetano N, Xiao Y, Erba E, Bassan R, Rambaldi A, Golay J, Introna M. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001;114(4):800–809.
   Google Scholar
• Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavin° M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol 2003;30(2):243–247.
   PubMed Web of Science ®Google Scholar
• Swords R, Nolan A, Fay M, Quinn J, O'Donnell R, Murphy PT Treatment of refractory fludarabine induced autoimmune haemolytic anaemia with the anti-CD20 mono-clonal antibody rituximab. Chin Lab Haematol 2006;28(1):57–59.
   PubMedGoogle Scholar
• Berentsen S, Tjonnfiord GE. Rituximab and fludarabine combination therapy for chronic cold agglutinin disease. [11th congress of the European Hematology Association, Amster-dam, Abstract 0027 J Haematologica 2006;91 (Suppl. 1):11.
   PubMedGoogle Scholar
• Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355 (12) :1233–1243 .
   PubMed Web of Science ®Google Scholar